Baseline characteristics of 471 patients with R/R B-ALL receiving first tisa-cel therapy
| Patient characteristics . | Total N = 471 . |
|---|---|
| Age at time of tisa-cel infusion, n (%), y | |
| Median (IQR) | 13.8 (7.8-19.5) |
| ≤10 | 157 (33.3) |
| 11-17 | 169 (35.9) |
| 18-39 | 145 (30.8) |
| Male sex, n (%) | 285 (60.5) |
| Recipient race, n (%) | |
| White | 340 (72.2) |
| African American | 32 (6.8) |
| Asian | 13 (2.8) |
| Native American | 3 (0.6) |
| >1 race | 17 (3.6) |
| Missing | 66 (14.0) |
| Karnofsky/Lansky score prior to tisa-cel, n (%) | |
| 90-100 | 299 (63.5) |
| 80 | 80 (17.0) |
| <80 | 63 (13.4) |
| Missing | 29 (6.2) |
| HCT-CI, n (%) | |
| 0 | 194 (41.2) |
| 1-2 | 149 (31.6) |
| 3-4 | 95 (20.2) |
| ≥5 | 21 (4.5) |
| Missing | 12 (2.5) |
| Prior history of infection before tisa-cel therapy | 53 (11.3) |
| Disease characteristics | |
| ∗Cytogenetics risk score overall (ALL), n (%) | |
| Normal | 46 (9.8) |
| Poor | 280 (59.4) |
| Other | 132 (28.0) |
| Not tested/unknown/NR | 13 (2.8) |
| Disease status at tisa-cel cell infusion, n (%) | |
| CR1 | 43 (9.1) |
| CR2 | 63 (13.4) |
| CR3 | 67 (14.2) |
| Relapse | 247 (52.4) |
| PIF | 51 (10.8) |
| MRD-positive/negative CR prior to tisa-cel (ALL), n (%) | 90 (19.1) |
| MRD–MRD+ | 78 (16.6) |
| Not in CR | 298 (63.3) |
| Not reported | 5 (1.1) |
| No. of lines of prior therapy, n (%) median (IQR) | 4 (2-5) |
| 1-2 | 128 (27.1) |
| 3 | 94 (20.0) |
| ≥4 | 230 (48.8) |
| Missing | 19 (4.0) |
| Prior therapy: blinatumomab, n (%) | |
| No | 354 (75.2) |
| Yes | 98 (20.8) |
| Not reported | 19 (4.0) |
| Prior therapy: inotuzumab, n (%) | |
| No | 401 (85.1) |
| Yes | 51 (10.8) |
| Not reported | 19 (4.0) |
| Prior HCT, n (%) | |
| No | 343 (72.8) |
| Yes | 119 (25.3) |
| Missing | 9 (1.9) |
| Patient characteristics . | Total N = 471 . |
|---|---|
| Age at time of tisa-cel infusion, n (%), y | |
| Median (IQR) | 13.8 (7.8-19.5) |
| ≤10 | 157 (33.3) |
| 11-17 | 169 (35.9) |
| 18-39 | 145 (30.8) |
| Male sex, n (%) | 285 (60.5) |
| Recipient race, n (%) | |
| White | 340 (72.2) |
| African American | 32 (6.8) |
| Asian | 13 (2.8) |
| Native American | 3 (0.6) |
| >1 race | 17 (3.6) |
| Missing | 66 (14.0) |
| Karnofsky/Lansky score prior to tisa-cel, n (%) | |
| 90-100 | 299 (63.5) |
| 80 | 80 (17.0) |
| <80 | 63 (13.4) |
| Missing | 29 (6.2) |
| HCT-CI, n (%) | |
| 0 | 194 (41.2) |
| 1-2 | 149 (31.6) |
| 3-4 | 95 (20.2) |
| ≥5 | 21 (4.5) |
| Missing | 12 (2.5) |
| Prior history of infection before tisa-cel therapy | 53 (11.3) |
| Disease characteristics | |
| ∗Cytogenetics risk score overall (ALL), n (%) | |
| Normal | 46 (9.8) |
| Poor | 280 (59.4) |
| Other | 132 (28.0) |
| Not tested/unknown/NR | 13 (2.8) |
| Disease status at tisa-cel cell infusion, n (%) | |
| CR1 | 43 (9.1) |
| CR2 | 63 (13.4) |
| CR3 | 67 (14.2) |
| Relapse | 247 (52.4) |
| PIF | 51 (10.8) |
| MRD-positive/negative CR prior to tisa-cel (ALL), n (%) | 90 (19.1) |
| MRD–MRD+ | 78 (16.6) |
| Not in CR | 298 (63.3) |
| Not reported | 5 (1.1) |
| No. of lines of prior therapy, n (%) median (IQR) | 4 (2-5) |
| 1-2 | 128 (27.1) |
| 3 | 94 (20.0) |
| ≥4 | 230 (48.8) |
| Missing | 19 (4.0) |
| Prior therapy: blinatumomab, n (%) | |
| No | 354 (75.2) |
| Yes | 98 (20.8) |
| Not reported | 19 (4.0) |
| Prior therapy: inotuzumab, n (%) | |
| No | 401 (85.1) |
| Yes | 51 (10.8) |
| Not reported | 19 (4.0) |
| Prior HCT, n (%) | |
| No | 343 (72.8) |
| Yes | 119 (25.3) |
| Missing | 9 (1.9) |
CR1, clinical remission 1; CR2, clinical remission 2; CR3, clinical remission 3; MRD, measurable residual disease; NR, not reported; PIF, primary induction failure.
Cytogenetics: normal, no abnormalities; poor: Ph+/t(9:22), t(4:11), 11q23, MLL, hypodiploid, t(8:14), complex cytogenetics; other, all other abnormalities.